Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy.

Abstract

Since cancer immunotherapy with immune checkpoint inhibitors of PD/PDL-1 and CTLA-4 limited efficacy to the patients due to resistance during the current decade, novel target is required for customized treatment due to tumor heterogeneity. V-domain Ig-containing suppressor of T cell activation (VISTA), a programmed death protein-1(PD-1) homolog expressed on T cells and on antigen presenting cells(APC), has emerged as a new target in several cancers. Though VISTA inhibitors including CA-170 are considered attractive in cancer immunotherapy to date, the information on VISTA as a potent biomarker of cancer prognosis and its combination therapy is still lacking to date. Thus, in this review, we discussed extracellular domain, ligands, expression, immune functions and clinical implications of VISTA and finally suggested conclusion and perspectives.

• Authors: Eunji Im, Deok Yong Sim, Hyo-Jung Lee, Ji Eon Park, Woon Yi Park, SeongGyu Ko, Bonglee Kim, Bum Sang Shim, Sung-Hoon Kim
• Journal: Seminars in cancer biology (Semin Cancer Biol) Vol. 86 Issue Pt 2 Pg. 1066-1075 (11 2022) ISSN: 1096-3650 [Electronic] England
• PMID: 34428551 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Chemical References

• Ligands

Topics

• Humans
• Ligands
• Immunotherapy
• Lymphocyte Activation
• Neoplasms (therapy, pathology)
• Prognosis